Charles A. McWherter
2013
In 2013, Charles A. McWherter earned a total compensation of $756.8K as Senior Vice President and Chief Scientific Officer at Cymabay Therapeutics, a 115% increase compared to previous year.
Compensation breakdown
| Bonus | $35,000 |
|---|---|
| Option Awards | $373,614 |
| Salary | $330,967 |
| Other | $17,230 |
| Total | $756,811 |
McWherter received $373.6K in option awards, accounting for 49% of the total pay in 2013.
McWherter also received $35K in bonus, $331K in salary and $17.2K in other compensation.
Rankings
In 2013, Charles A. McWherter's compensation ranked 7,801st out of 12,286 executives tracked by ExecPay. In other words, McWherter earned more than 36.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,801 out of 12,286 | 37th |
Division Manufacturing | 2,819 out of 4,612 | 39th |
Major group Chemicals And Allied Products | 876 out of 1,462 | 40th |
Industry group Drugs | 663 out of 1,156 | 43rd |
Industry Pharmaceutical Preparations | 525 out of 890 | 41st |
Source: SEC filing on April 21, 2014.
McWherter's colleagues
We found two more compensation records of executives who worked with Charles A. McWherter at Cymabay Therapeutics in 2013.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019